| abstract |
To a human or other mammal, a pharmaceutical composition containing a cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate or polymorph thereof, from about 65% to about 110% is used one, two or three times per month. Methods comprising oral administration in accordance with a continuous dosing schedule of consecutive days are useful for the treatment or prevention of osteoporosis and other bone metabolic disorders. |